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1. Abstract  
 
1.1. English Version  
Objective: Brainstem tumors account for about 10-20% of all primary paediatric tumors 
in the central nervous system. Approximately 75% of all brainstem tumors in children 
are diffuse pontine gliomas (DIPG) and the median overall survival is less than a year. 
Due to its infiltrative character and anatomical location, surgical resection is not 
considered as therapeutic option. It was described that expression of HO-1 is 
associated with growth activity of cancer cells, which suggests that a specific inhibitor of 
HO-1, ZnPP, may work as a potent antitumor therapeutic agent. To evaluate the 
antitumor efficacy of PEG-ZnPP, a water soluble derivate of ZnPP, we performed 
studies in vitro and in vivo brainstem glioma models.  
 
Methods: To evaluate the antitumor efficacy of PEG-ZnPP in vitro, proliferation assay 
on glioma cell lines C6 and F98 was performed. Based on the results of our proliferation 
assay, apoptotic activity using conjugate of annexin V was evaluated and cell cycle 
analysis was assessed. After in vitro study, we performed systemic therapy with PEG-
ZnPP in rat brainstem tumor models with F98 and C6. Neurological status and survival 
rate was monitored.  
 
Results: This project demonstrated that PEG-ZnPP significantly inhibits rat glioma cell 
proliferation and induces a significant level of apoptosis in C6 and F98 glioma cell lines, 
suggesting that PEG-ZnPP may represent a potential anticancer agent for brain tumors. 
In vivo study on rat brainstem glioma models, however, showed no differences of 
survival between the control group and animals receiving intravenous PEG-ZnPP 
therapy.  
 
Conclusion: In contrast to in vitro studies systemic administration of PEG-ZnPP did not 
improve the survival on the rat brainstem glioma model suggesting that different 
approaches and additional animal research are required to overcome the BBB and to 




1.2. Deutsche Version  
 
Einleitung: Tumore des Hirnstamms machen ca. 10-20% aller primären Tumoren des 
zentralen Nervensystems im Kindesalter aus. Zirka 75% aller Tumore im Hirnstamm 
sind die diffus intrinsischen Ponsgliome (DIPG) und deren mediane Lebenserwartung 
beträgt weniger als ein Jahr. Aufgrund des infiltrativen Charakters und deren 
Lokalisation kommt die Resektion als therapeutische Option nicht in Frage. Es ist 
bekannt, dass erhöhte Expression der HO-1 mit einem raschen Wachstum von 
Tumorzellen assoziiert ist, sodass eine spezifische Inhibition der HO-1 mittels PEG-
ZnPP, eine wasserlösliche Form von ZnPP, als eine anti-tumorale Therapie möglich 
erscheinen lässt. In dieser Studie wurde antitumorale Wirkung von PEG-ZnPP 
innerhalb von in vitro Analyse und in vivo im Hirnstammgliom Modell bei der Ratte 
durchgeführt.  
 
Methoden: In der vitro Untersuchung erfolgte zur Evaluation der antitumoren 
Effektivität eine Proliferationsanalyse in den F98 und C6 Gliomzelllinien. Anschließend 
erfolgte in einer vivo Studie die Implantation von F98 und C6 Gliomzellen in den 
Hirnstamm der Ratte gefolgt von einer systemischen Gabe von PEG-ZnPP. Der 
neurologische Status und das Körpergewicht der Ratte wurden im Verlauf dokumentiert 
und die Überlebensrate der Tiere bestimmt. 
 
Ergebnisse: Diese Studie konnte in den in-vitro Untersuchungen die signifikante 
Hemmung der Gliomzell-Proliferation durch PEG-ZnPP zeigen. Demgegenüber zeigten 
die in-vivo Untersuchungen keine Unterschiede der Überlebensrate der PEG-ZnPP 
behandelten Tiere im Vergleich zu den Kontrolltieren.  
 
Schlussfolgerung: Trotz der antitumoralen Wirkung von PEG-ZnPP in vitro zeigte die 
systemische Applikation im Hirnstammgliom Modell keine überlebensverlängernde 
Wirkung der Ratte. Am ehesten scheint die Blut-Hirn-Schranke eine relevante Barriere 
für PEG ZnPP zu sein welches diese Diskrepanz erklären könnte. Als Herausforderung 
bleibt neue Versuchsverfahren zur Überwindung der Blut-Hirn-Schranke zu finden, um 




2. Introduction  
 
2.1. Brainstem Glioma  
 
Brainstem tumors refer to heterogeneous tumor lesions in the midbrain, the pons or the 
medulla oblongata. These tumors are uncommon in adults, but in children represent 15-
20% of all primary paediatric tumors in the CNS [1, 2]. Brainstem glioma can be 
subdivided into focal and diffuse subtypes. Further classification of the brainstem glioma 
is various. Typically brainstem tumors can be classified according to MR imaging and 
divided according to their location in the midbrain, pons or medulla [3]. Currently based 
on anatomical characters on the MR imaging, it can be classified into the following 
subgroups: tectal tumors, diffuse intrinsic pontine glioma (DIPG), focal tumors, dorsal 
exophytic tumors and cervicomedullary tumors [4]. It can be also classified according to 
imaging and predominant pathologic characteristics: diffuse intrinsic, focal midbrain, 
dorsal exophytic and cervicomedullary tumor type [5].  
The most common tumor type among brainstem tumors is the DIPG, which accounts for 
75-80% of brainstem tumors in children [6, 7].  Clinical symptoms of DIPGs and non-
DIPGs include headache, vomiting, nausea, double vision, ataxia and cranial 
neuropathies. In cases of DIPGs, delay between first signs and the diagnosis is shorter 
than in cases of non-DIPG cases: less than 3 months [8]. Classic morphology of DIPG 
on MRI include a mass in the middle of the pons, encompassing more than 50% of the 
pons, and causing enlargement of the pons [8]. Some authors defined DIPG as virtually 
all gliomas in the diffuse masses, which occur as expansive mass lesion within the 
ventral pons [5]. In the majority cases with DIPG, little or no enhancement of the mass 
after applying of gadolinium is characteristic [8]. It is known that between 20 and 30 
diffuse pontine gliomas occur in the UK annually [9] and between 100 and 150 a year in 
the USA [10]. DIPG is highly aggressive and prognosis is very poor. Median survival in 
children with diffuse brainstem glioma is less than a year [2].   
 
 
2.2. Current Therapeutic Strategies 
 
Other than DIPGs, non DIPGs including tectal, focal, dorsal exophytic and 
cervicomedullary tumors are typically low grade, and based upon anatomical location, 
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size, focality of the mass and tumor growth pattern, attempts at surgical resection or 
biopsy can be performed [4].  In addition to surgical treatment, radiation and 
chemotherapy are available depending on neuropathological diagnosis.  
However, due to the infiltrative character and anatomical location of the DIPGs, it has 
been regarded that surgical treatment is generally not possible, and due to potential 
complications, biopsies have been rarely performed in the past. The presumptive 
diagnosis of DIPG can be performed based on MR imaging characteristics, which may, 
however,  limit potential development of the possible therapy as no tumor 
characteristics can be further investigated, and even a small number of cases have 
been reported, which were thereby misdiagnosed [8]. 
Since no homogenous therapy guideline for the DIPGs is available, several therapy 
methods including chemotherapy, adjuvant chemotherapy, and chemo-radiotherapy 
have been suggested, however, none of these published trials have proved significant 
benefit of survival yet.  
Survival duration varies between trials of chemotherapy administration prior to 
radiotherapy, chemotherapy before and after radiotherapy, concomitant chemotherapy 
and radiotherapy and chemotherapy immediately following radiotherapy [1]. 
Neurological improvement and reduction of glucocorticoid medication could be achieved 
through conventional radiotherapy, but a significant association between radiotherapy 
and extension of overall survival has not been shown [1].  
Currently, the mainstay of the treatment of DIPGs remains focal radiation therapy to the 
pons with 3D conformal photon-based radiotherapy to a range of 54-59.4 Gy [8]. This 
can be given in 30-33 fractions of 1.8 Gy daily [8]. However, the optimal fractionation 
has not been defined.  
Multiple trials investigating benefit of combination with radiotherapy for brainstem tumor 
have shown disappointing results [1, 11]. Given the unsatisfactory results from current 
chemotherapeutic agents, better promising chemotherapeutic agents need to be 
explored.  
 
2.3. Animal Model  
 
In order to develop novel therapeutic agents, reliable experimental animal models for 
brainstem tumors are essential. For this purpose, an accessible and reproducible 
brainstem tumor model was developed by Jallo et al. and Thomale et al [12, 13]. This 
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model shows a reproducible course of onset of neurological deficit and predictable 
tumor histology and allows monitoring and functional testing of rats with brainstem 
tumor [12]. Jallo et al. implanted F98 and 9L cell lines, which showed a predictable 
pattern of tumor infiltration, and in 80-90% of animals tumor production was confirmed 
[14]. This developed model is amenable to monitoring and functional testing and also 
demonstrated the infiltrative nature of human brainstem tumors [12].  
 
 
2.4. PEG-ZnPP  
 
2.4.1. Heme Oxygenase  
 
HO is a microsomal enzyme and catalyses the first rate limiting step in the degradation 
of heme cleaving the heme to produce biliverdin, accompanied by production of carbon 
monoxide [15]. Iron ions and biliverdin derivated from this process play an important 
role in recycling of iron [16, 17]. HO cleaves the meso-carbon bridge of heme, yielding 
equimolar quantities of carbon monoxide (CO) [18]. Free iron induces the expression of 
the iron-sequestering ferritin and activates Fe-ATPase, an iron transporter, which 
decreases intracellular Fe2 content [19]. Biliverdin is converted to bilirubin by biliverdin 
reductase [20]. Bilirubin is known as a potent antioxidant [21].  
There are three identified HO isoforms catalysing heme degradation. HO-1,  the 
oxidative stress-inducible protein, also known as HSP32 [16] and the constitutive 
isoenzyme HO-2 were first introduced and then HO-3, which is expressed in various 
organs in rats, similar to HO-2, but with a much lower catalytic activity [22]. These three 
isoforms are products of different genes [15].  
HO-1 and HO-2 show different characteristics. It is known that HO-2 is abundant in 
brain and testis [23]. HO-1 is synthesized mainly in microglia, in neuronal cells and 
known as one of several related heme oxygenase proteins that metabolize heme to CO 
and biliverdin, with the release of iron [24]. Among those isoforms, HO-1 can be 
induced in response to various cellular stresses and oxidative stimuli including heme 
[25], ultraviolet irradiation [26], hydrogen peroxide [26], heavy metals [26], [27], heat 
shock [25], hypoxia [28] and nitric oxide (NO) [19, 29, 30]. Cells protect themselves 
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from such stressful environments by producing protective protein, termed heat-shock 
protein [31].  
HO-1 plays a protective role working as a potent anti-inflammatory enzyme in the 
cellular environment. HO-1 deficiency results in sustained oxidative stress, accentuated 
oxidative damage in the cardiovascular system and progressive chronic inflammation in 
the kidney and liver [19].  There are data suggesting that overexpression of HO-1 may 
defend tissues and organs from immune-mediated injury, either through protection 
against oxidative damage or via a local immunomodulatory influence on infiltrating 
inflammatory cells [32, 33]. The exact mechanism has not been elucidated. The 
signaling action of CO with biliverdin/bilirubin and the sequestration of the iron ion 
contribute to this anti-inflammatory role [19].  
HO-1 works not just as an anti-inflammatory enzyme, but also as a cytoprotective 
enzyme in tumor cells protecting them from oxidative stress, hypoxia, serum deprivation 
or toxic compounds [19]. The mechanism of the anti-proliferative effect of HO-1 in many 
cells has not been clearly elucidated. The cytoprotective role of HO-1 for tumor cells 
was confirmed by studies which demonstrated that pharmacologic or genetic 
upregulation of HO-1 improves survival of various tumors including hepatoma [29], 
melanoma [34], thyroid carcinoma [35], chronic myelogenous leukemia [36], gastric 
cancer [37] and colon cancer cell lines [38]. Biliverdin, one of the products of heme 
degradation, plays an important role in protecting cells from oxidative stress by 
scavenging free radicals, such as peroxy radicals [39], preventing protein oxidation by 
the potent reactive nitrogen species peroxynitrite [40] and protecting neuronal cells from 
oxidative stress injury [41]. 
HO-1 is often upregulated in quickly proliferating cells such as cancer cells [42]. High 
expression of HO-1 induced by pharmacologic or genetic manipulation is associated 
with faster tumor growth, expressed as large volume of nodules or more numerous 
cancer cells [19]. Upregulation of HO-1 decreases cell proliferation, and the 
antiproliferative effect is reversed by HO-1 inhibition [43]. Targeted knockdown of HO-1 
expression lead to growth inhibition of pancreatic cancer cells [44] 
HO-1 is upregulated in various tumors including lymphosarcoma [45], adenocarcinoma 
[46], hepatoma [29], melanoma [47], prostate cancers [42], Kaposi sarcoma [48], 
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squamous carcinoma [49], and pancreatic cancer [44]. There are data reporting the 
higher level expression of HO-1 in human brain tumors compared to the brain tissue 
[50]. Deininger et al. [51] demonstrated prominent accumulation of HO-1 expression in 
glioblastoma cells. Sahoo et al. [52] found that tumor cells utilize HO to protect 
themselves from oxidative stress by producing the antioxidant bilirubin.  
Interestingly, expression of HO-1 in cancer cells can be further increased in response to 
chemotherapy and radiation [44]. Duckers et al. demonstrated that the upregulation of 
HO-1 decreases cell proliferation and inhibiting HO-1 reverses the anti-proliferative 
effect [43]. This finding may support that HO-1 plays an important role for regulation of 
cancer cells.  
 
2.4.2.  Anti-Apoptotic Effect of HO-1 
One of functions of HO-1 is associated with apoptosis, which plays a pivotal role in the 
pathogenesis of cancer. One of the mechanisms associated with carcinogenesis is that 
too little programmed cell death, termed as apoptosis, occurs in cellular cascade so that 
defect cells are not eliminated. Apoptosis is well associated with carcinogenesis so that 
it is considered as an important target of anticancer treatment strategies. Anti-apoptotic 
efficacy of HO-1 has been demonstrated in in vitro and in vivo studies [35-38, 53]. 
Another important point is that anti-apoptotic effects of HO-1 can be associated with the 
anti-oxidative function of HO-1, as ROS are the inducers of apoptosis [54]. CO, which is 
one of products of HO-1, blocks the release of the mitochondrial cytochrome 1 and 
inhibits expression of the p53 [55]. P53 promotes apoptosis through the caspase 
pathway through mitochondrial cytochrome c release [56].  
 
2.4.3. Pro-Angiogenic Effect of HO-1 
HO-1 is also known as a proangiogenic enzyme. As angiogenesis is essential for tumor 
proliferation, understanding the mechanism of the angiogenesis may bring a key 
component for understanding cancer cell biology. Cisowski et al. demonstrated that HO-
1 deficient endothelial cells can produce less VEGF than their wild type counterparts do 
[57], which supports the proangiogenic action of HO-1 in tumor proliferation. In vivo and 
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in vitro experiments in the rat model, it was demonstrated that HO-1 gene transfer 
increased VEGF synthesis, facilitating angiogenesis, which results in improving the 
blood flow in in vivo experiments [58].  
As described above, HO-1 plays a protective role for tumor cells, however it works also 
as a cytoprotective agent in non-cancer cells exposed to carcinogens [19]. According to 
Jozkowicz et al. [19], it can be hypothesized that HO-1 may increase the resistance of 
cells to harmful stimuli and cellular stresses. Currently the role of HO-1 in 
carcinogenesis has not been fully elucidated.  
Overall the characteristics of HO-1 including angiogenesis, cytoprotection for tumor 
cells, carcinogenesis and anti-apoptosis contribute to tumor cell proliferation. This 
suggests that therapy inhibiting HO-1 may lead to cancer cell vulnerability towards 
oxidative stress [52], which could be utilised as potential strategic target for anticancer 
therapeutic development.  
 
2.4.4. ZnPP as a Competitive Inhibitor of HO 
ZnPP is a member of metalloporphyrins, in which the heme iron is replaced by zinc, and 
is known as a competitive HO-1 inhibitor [59, 60].  Metalloporphyrins are compounds in 
which the central iron of heme is replaced by other metals including chromium, cobalt, 
manganese, zinc or tin [61].  The function of metalloporphyrins as competitive inhibitor 
to HO is due to their inefficient binding to molecular oxygen, so that HO becomes 
unfunctional [17, 61].  
 
2.4.5. ZnPP Conjugated with PEG  
As it is validated that ZnPP can inhibit HO-1, which plays a pivotal role in tumor growth, 
inhibiting HO-1 and thus providing the antioxidant bilirubin, this suggests a potential 
therapeutic antitumor strategy. However, due to the very low solubility of the 
metalloporphyrin aqueous media, its utility as a systemic therapy agent has been 
hampered. Sahoo et al. [52]  developed a water soluble derivative of ZnPP by 
conjugating it with the water soluble polymer, PEG. Aside from having its original 
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function of ZnPP, the inhibiting of HO, this water soluble compound behaves as a 




     2.5. Enhanced Permeability and Retention Effect 
 
In tumors, the vasculature is distinct from normal vasculature in a way that the 
aggressive growth of the neoplastic cells and overexpression of proangiogenic factors 
induce the disorganized blood vessel network. They are more permeable than normal 
vessels, and the density of smooth muscle cells is poor and composed of a 
discontinuous endothelial cell lining with an abnormal basement membranes [62, 63]. 
Irregular vascular shape and vessel network formation may cause poor delivery of 
oxygen, and consequently micro regional hypoxia can be induced [64, 65]. This hypoxic 
environment can cause downstream signalling of pro-angiogenic proteins, which 
eventually lead angiogenesis and therefore malignant progression [66, 67]. This unique 
feature of tumor vasculature effects on cancer therapeutic strategy. The phenomenon 
termed as enhanced permeability and retention (EPR) effect [52, 68] causes the tumor 
specific accumulation of biocompatible macromolecules and lipids when it is 
administered systemically [69]. According to Masumura and Maeda et al. [68-71], EPR 
effects are mainly based on the following four features: 1. Hyper-vasculature of tumor 
tissues. 2. Leaky structure of tumor blood vessels. 3. Enhanced production of vascular 
mediators including NO and bradykinin. 4. Incomplete lymphatic drainage system.  
These concepts were validated by demonstrating that systemic administration of 
conjugated ZnPP achieved effective and selective delivery of the HO inhibitor to tumor 
sites [52].  
Maeda et al. found time-dependent accumulation of PEG-ZnPP in tumor tissue and 
gradual decrease in circulation, which may suggest that PEG-ZnPP accumulates or is 
deposited in solid tumor tissues after systemic administration [72]. Sahoo et al. reported 
that the enhanced permeability and retention effect of PEG-ZnPP may contribute to 








Figure 1. EPR effect  [73, 74] Schematic illustration of the enhanced permeability and retention 
(EPR) effect of molecules with high molecular weight and low molecular weight. Due to leaky 
and permeable vascular structure, only few of low molecular weight stay inside the tumor tissue 
and the majority of them are again eliminated from the circulation rapidly. On the other hand, 
high molecular weight drugs including biocompatible macromolecules and lipids are distributed 
and accumulated in the tumor tissue. A relatively low concentration of these drugs is eliminated 
from the systemic circulation. Image kindly provided by YL Kang. 
 
 
3. Purpose of this study 
 
In various solid tumor models, therapy with PEG-ZnPP proved its antitumor efficacy. To 
our knowledge there have been no in vitro studies which evaluated the efficacy of PEG-
ZnPP on rat glioma cell lines.  
The purpose of the study was to assess the antitumor activity of PEG-ZnPP on glioma 
cell lines C6 and F98 proliferation in an in-vitro setup. An in vivo study design was to 
assess the effects of systemic administration of PEG-ZnPP in a rat brainstem glioma 
model to monitor body weight and neurological function and to evaluate the survival in 






4. Materials and Methods  
 
4.1. In Vitro  
 
4.1.1. Cell lines and culture Conditions 
 
Two rat glioma cell lines, F98 and C6, which were purchased from the ATCC Cell 
Biology Collection, were used. F98 and C6 cell lines are widely used for rat brain tumor 
models and various studies. The F98 line was developed in BD IX rats using a single 
intravenous injection of N-ethyl-N-nitrosourea administered to a pregnant animal on the 
20th day of gestation [75].  F98 cells show a highly invasive pattern of growth [76]. The 
C6 cell lines were produced by administering methyl nitrosourea to outbred Wistar rats 
[77, 78]. The C6 cell lines are a popular model, which is used in experimental neuro-
oncology to evaluate the therapeutic anticancer efficacy [76].  
These cells were routinely maintained in Dulbecco’s Modified Eagle Medium (DMEM, 
Lonza, USA) supplemented with 10% fetal bovin serum (FBS, Gibco, Invitrogen, USA) 
and 1% 100 U penicillin / 0.1 mg/ml streptomycin (Invitrogen, USA) in cell culture flasks. 
The medium was renewed about twice a week, and the cells were subcultured while 
renewing the medium regularly. The cells in flasks were incubated at 37C° in 5% CO2 
humidified incubators. For washing the cells, phosphate buffered saline (PBS, pH 7.4 
(1X), (-) CaCl2, (-)MgCl2, Gibco, USA) was used.  
PEG-ZnPP was synthesized by Professor Maeda and Professor Fang (Department of 
Microbiology, Kumamoto University School of Medicine, 2-2-1 Honjo, Kumamoto 860-
0811, Japan) [52] and kindly provided.  
 
 
4.1.2. Proliferation assay 
 
For proliferation assay, rat glioma cells, F98 and C6, were seeded at a density of 
2.5x104 cells/well in a 6-well culture plate. These were treated with 40 μM PEG-ZnPP 
or phosphate buffered saline (PBS, Lonza, USA) as vehicle, grown over time in DMEM-
high glucose with 10% FBS and 5% CO2 and assessed for viable cell numbers over 6 
days. The treatment with PEG-ZnPP was started 6 hours after seeding. The number of 
cells was monitored every other day. The final day of monitoring was day 6. This setup 
 17 
was repeated four times. Cells were then collected at the indicated time in 1mL of 
trypsin (Lonza, USA) and washed with PBS. 20 µL of cell suspension were mixed with 
20 μL of Trypan Blue (Lonza, USA). Cells were counted using a Malassez slide 
(Invitrogen, Life Technologies, USA) and the number of cells per milliliter was 
determined by the following formula: n = (Cell numbers /20 squares) x 2 x 100 x 1000, 
in order to assess the cell proliferation over time.  
 
 
4.2. In Vivo  
 
4.2.1. Cell Preparation for the in vivo Study 
 
For the in vivo part of the experiment, cells were carefully suspended in media and 
transferred to centrifuge tube for about 7 minutes. The supernatant was removed and a 
pellet at the bottom of the tube was suspended in a media for further cell counting. The 
tumor cells were counted with a hemocytometer, and were diluted with media to a 
concentration of 1.0 × 105 cells/3 μl. Cell preparation was done directly before the cell 





For the first in vivo experiment (Group A), a total of 17 male Sprague Dawley rats 
(Charles River Laboratories, Wilmington, MA, USA) weighing 250 to 350g were used. 
Randomly, 8 rats were assigned to control group and 9 rats to therapy group. For the 
second in vivo experiment (Group B), 15 female Fischer rats (Charles River 
Laboratories, Wilmington, MA, USA) weighing 130 to 160 g were used. To control group 
6 rats and to therapy group 9 rats were assigned, respectively. The rats were housed in 
standard facilities and were given free access to Baltimore City water and rat chow. The 
experimental protocol was approved by the Animal Care and Use Committee of the 
Johns Hopkins University and the use of all study animals conformed to the National 
Institutes of Health Rules Guide for the Care and Use of Laboratory Animals (National 
Academy of Science). 
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4.2.3. Rat Brainstem Model - Surgery 
Rats were anesthetized with an intraperitoneal injection of 3mL/kg of a stock solution 
containing 75 mg/mL ketamine hydrochloride (Ketathesia, Butler Animal Health Supply, 
USA), 7.5 mg/mL xylazine (Lloyd Laboratories, USA); and 14.25% ethyl alcohol (Fisher 
Scientific, USA) in 0.9% NaCl. Heads were shaved with clippers and prepared with 
prepodyne solution (West Penetone, USA). All surgical procedures were performed 
using standard sterile condition. The surgery for tumor cell implantation within the 
pontine brainstem was performed as described by Jallo et al. and Thomale et al. [12, 
13]. In 17 Sprague Dawley rats (the first group) and 15 Fischer rats (the second group) 
a guide screw was positioned in a burr hole 1.4 mm right of the sagittal, and 1.0 mm 
anterior of the lambdoid sutures, at a depth of 7.0 mm from the dura. The head was 
positioned 5° from horizontal before injection of tumor cells. A 22-gauge 10-μl Hamilton 
needle (Hamilton Company, Reno, NV, USA) was inserted to a depth of 7 mm from the 
dura mater (figure 2). The first group received 3 μl of C6 glioma cells (100,000 cells) 
and the second group received 3 μl of F98 glioma cells (100,000 cells). To avoid cell 
leakage or backflow of the media, the insertion of tumor cells was performed slowly and 
the needle rested for 3 minutes before removal. After skin closure and recovery, the 
animals were returned to their cages. Each animal was subsequently evaluated for 








Figure 2A. Schematic illustration of surgical technique for tumor cell implantation within the 
pontine tegmentum. This illustration shows the position of a burr hole for tumor cell implantation. 
The burr hole is positioned 1.4 mm right of the sagittal and 1.0 mm anterior of the lambdoid 







Figure 2B. This illustration shows axial section of the tumor cell implantation. After the 
cannulated guide screw is implanted on the calvarium, the Hamilton needle is inserted through 
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the cannulated guide screw at the intended target, the pontine tegmentum (approximately 7 
mm from dura level) [12]. Image kindly provided by YL Kang. 
 
 
4.2.4.  Systemic administration 
In the first in vivo trial on Sprague Dawley rats (Group A), intravenous treatment with 
PEG-ZnPP was begun on the forth post-tumor implantation day and performed every 
other day on tail vein (total of 4 times). The injection dose of PEG-ZnPP was equivalent 
to 5 mg of ZnPP/kg (concentration of 1.75 mg/0.1 ml PBS).  
In the second in vivo trial on Fischer rats (Group B), intravenous treatment with PEG-
ZnPP was begun on the third post-tumor implantation day and performed every other 
day on tail vein (total of 4 times). In Group B, Fisher Rats received injections of PEG-
ZnPP equivalent 7.5 mg/kg ZnPP/kg (concentration 1.75 mg/0.1 ml PBS). The 
intravenous treatment dose of PEG-ZnPP was based on the previous study of Fang et. 
al  [72] and adjusted according to Equivalent Surface Area Dosage Conversion Factors 
[79]. For tail vein injection, rats were anesthetized with an intraperitoneal injection of 
3mL/kg of a stock anesthesia solution with the same combination for tumor implantation. 
As the rats were anesthetized, they were positioned in a tail-first restrainer.   
 
 
4.2.5. Neurological monitoring  
Neurological motor scores applied for each extremity were measured daily after F98 
glioma cell implantation on the Fisher rat group. This neurological scoring system, the 
Berlin Baltimore Brainstem (BBB) score previously described by Thomale et al. [13] 
(table 1), was applied. BBB is a modified scoring system used for cerebral ischemia [80, 
81], which evaluates motor function of the extremities and each extremity can have a 
maximum value of four and a minimum value of zero. According to the scoring system, 
a total of 4 points for cases of complete plegia of one limb could be applied with  
possible additional 2 points for abnormal movement, such as tilted head to the side or 
axial body rotation [13]. However, the total possible score on the rating scale was not 
supposed to be reached, because rats that scored 14 points and above were 
euthanized according to the experimental protocol to avoid any extreme suffering of the 
animals.  
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The neurological monitoring for the motor abilities of the rats was carried out on a 
secured surface measuring 120 cm x 90 cm. Each rat was observed long enough until 
neurological scoring of each extremity was clearly determined.  
 
Motor Score 0 No deficit 
 1 Able to walk with slight asymmetry 
Decreased resistance when pushed from the contralateral side 
 2 Walk with obvious asymmetry 
 3 Slight movement present, with no use for walking 
 4 No movement 
Points added for  
abnormal movement 
1 Tilted head to the side 
 2 Axial body rotation 
Total score 0-18  
 
 Table 1.   Berlin-Baltimore brainstem neuro-score [13] 
 
 
4.2.6. Weight Measuring 
As weight loss characterizes the morbidity status of cancer [82],  the weight changes of 
rats over time were measured daily. This measurement was carried at the rat housing 
room.  
 
4.3. Statistical Analysis  
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Analysis and calculations were performed using Prism 7 GraphPad software (Prism, CA, 
USA). Results are expressed as means ± standard error of mean (SEM), or as stated 
otherwise.  
To calculate the value of the test statistic (p-values) of in vitro studies, weight changes 
and neurological changes, the Mann-Whitney-U-Test, one of the nonparametric tests, 
was applied, as this test compares the means of outcomes of two independent groups 
(control group vs. treated group), with the assumption of the data not being normally 
distributed. The two- tailed p value was applied, as there is no previous data regarding 
the efficacy of PEG-ZnPP on glioma cell lines.  
For survival analysis, the logrank test (Mantel-Cox method) [83], which is the most 
commonly used method for comparing the survival distributions of two groups, was 
applied. This logrank test is used to test the null hypothesis with no differences in 
survival event, which is the events of death, between two or more independent groups 
[83]. The survival curves were created using Prism 7 GraphPad software (Prism, CA, 








5.1. In Vitro 
 
5.1.1. Effect of PEG-ZnPP on Rat Glioma Cells: Anti-Proliferation  
 
To assess the potential anti- proliferative effects of PEG-ZnPP on rat glioma cell growth, 
the proliferation assays of C6 and F98 glioma cell lines were performed and evaluated 
by counting cell numbers after treating with 40 μM PEG-ZnPP or PBS. Results show 
that the control group and the group treated with PEG-ZnPP show continuous 
proliferation of both glioma cell lines (Table 2 and Table 3). However, in the group with 
PEG-ZnPP treatment the cell numbers in the F98 cancer cell line were significantly 
decreased compared with control (*p<0.05, PEG-ZnPP vs. Ctrl, n = 4; figure 3). F98 
glioma cell lines revealed profound growth inhibition under the influence of PEG-ZnPP. 
This significant inhibition of proliferation in PEG-ZnPP added cultures was seen at day 











Table 2. The proliferation assay was performed a total of 4 times. (values are given as mean ± 
standard error of mean), Control group vs. treatment group of C6 cell lines (n=4). P-values are 





                      Cell Counts of C6 cell lines    
Day n Control Treated 
   
0 4 25000 25000    
2 4 353137,5±38387,8 293562,5±43091,28 
   
4 4 1814025±187503,57 1285725±277396,48 
   
6 4 10700825±1453804,15 7074031,25±1230657,81 







Table 3. The proliferation assay was performed a total of 4 times. (values are given as mean ± 
standard error of mean), Control group vs. treatment group of F98 cell lines (n=4). P-values are 






Figure 3.  PEG-ZnPP inhibits rat glioma cell proliferation  
F98 and C6 glioma cells were seeded at a density of 2.5x104cells/well and grown for up to six 
days. In them, 40μM PEG-ZnPP or PBS (Lonza, USA) as a vehicle was added.  Day 0: cell 
number: (2.5x104). (A) Proliferation assay performed with C6 cells showing at day six after 
treatment a decrease in cell number compared to vehicle-treated cells. (B) Proliferation assay 
performed with F98 cells showing at day six after treatment a significant decrease in cell 
number compared to vehicle-treated cells. Data are mean ± SEM *p<0.05, PEG-ZnPP vs. 
Control, n=4. P-values are calculated via Mann-Whitney U Test Calculator (two-tailed) 
 
 
                   Cell Counts of F98 cell lines    
Day n Control Treated    
0 4 25000 25000 
   
2 4 208000±17813,85 208000±23352,37    
4 4 1090250±120901,04 847475±156324,49    
6 4 5020275±557290,24 2585650±463360,06* 
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5.2. In Vivo 
Systemic treatment with PEG-ZnPP did not show efficacy in the brain stem model.  
Based on our in vitro results, particularly the inhibition of proliferation in response to 
PEG-ZnPP treatment, we performed in vivo experiments to evaluate the anticancer 
therapeutic efficacy of PEG-ZnPP.  
 
 
5.2.1. Weight changes 
 
In the Group A Sprague Dawley rats, body weight increased until the 16th postoperative 
day in both groups with treatment and without treatment. Weight gain in the control 
group was more pronounced than in the group with treatment, which showed significant 
differences at days 6, 8, 10, 12, 14 and 16.  
In the Group B Fischer rats with PEG-ZnPP treatment, body weight remained stable 
before it begun to decrease between 15th and 17th postoperative days. In control rats, 
an early weight gain was observed followed by a weight loss, which occurred earlier 






Table 2. Weight changes (values are given as mean ± standard deviation). CG: Control group, 




Sprague Dawley rats body weight changes [g]  
Days 2 6 8 10 12 14 16 18 21 
CG 373.1±24 383.8±21 393.1±17 399.4±18 402.5±19 409.4±18 418.1±19 413.1±25 392.1±38 
TG 368.3±37 350.6±31* 350.6±31* 355±30* 360±28* 370±31* 385.7±39* 385.6±44 371.9±60 
  
Fisher rats body weight changes [g]  
Days 3 5 7 9 11 13 15 17 19 21 
CG 152.5±8 162.5±8 161.7±8 161.7±9 162.5±8 162.5±8 156.7±11 147.5±15 138±19 131.3±14 
TG 149.4±11 150±10* 152.8±9 144.3±7* 145±10* 146.4±7* 147.1±10 142.9±13 132±14 121±5 
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5.2.2. Neurological monitoring.  
 
Neurological changes were monitored in Fischer rats (group B). In the control group, 
neurological deficits began to occur from day 15. In the treatment group, they occurred 
from the day 17. During this period, weight loss was also progressive. Once the 
neurological deficits began to occur, a progressive worsening of neurological 
performance was observed without any significant differences among the groups (Table 
3). As the total score reached 14 points for an individual rat (maximal possible score: 18 
[13]), rats were euthanized according to the experimental protocol.  
 
 
Table 3. Neuroscore changes of Fischer rats (values are given as mean ± standard deviation). 
CG: Control group, TG: Therapy group.  (* p<0.05). P-values are calculated via Mann-Whitney 




5.2.3. Survival Rate 
No difference in overall survival between the group with intravenous PEG-ZnPP therapy 
versus control group was observed (Figure 6). In the group A Sprague Dawley rats with 
PEG-ZnPP treatment, the median survival was 23 days (range: 21-49 days). Control 
rats without therapy had a median survival of 24 days (range: 20-48 days; p = 0.47; log-
rank test).  
In the group B with Fisher rats, used in the second experiment, median survival of rats 
was 22 days (range: 9-26 days) with therapy, versus 22.5 days (range: 29-25 days) 
without therapy (p = 0.73; log-rank test). There were no differences of survival periods 
between the groups with therapy and without therapy.  
 
Days 3 5 7 9 11 13 15 17 19 21 
CG 0±00 0±00 0±00 0±00 0±00 0±00 0.17±0.4 2.17±2.3 5.8±4.5 5.8±4.6 




































Fig. 6. Survival rates of brainstem tumor models after intravenous treatment with PEG-ZnPP 
 (A) Group A with PEG-ZnPP via I.V. in Sprague Dawley rats, male (C6 cells implanted): Dose: 
equivalent 5 mg of ZnPP/kg, Concentration 1.75 mg/0.1 ml PBS, Control: 8 rats, Therapy: 9 rats. 
Intravenous treatment was performed on days 4, 6 and 7 after tumor implantation. The median 
survival of rats with the PEG-ZnPP, 23 days (range: 21-49 days (1= Censored subject)); rats as 
control, 24 days (range: 20-48 days), P=0.47; log-rank test  
(B) Group B with PEG-ZnPP via I.V. in Fischer rats (F98 cells implanted): Dose: equivalent 7.5 
mg/kg ZnPP/kg. Concentration 1.75 mg/0.1 ml PBS, Average weight = 143.7 g, Control: 6 rats, 
Therapy: 9 rats. On 3, 5, 7 and 9 post-tumor implantation days, intravenous treatment was 
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performed. The median survival of rats with the PEG-ZnPP: 22 days (range: 9-26 days); rats as 






Since the potent anticancer effect of ZnPP appeared to be promising, several studies 
have been carried out investigating preclinical and clinical application of ZnPP, which 
was somewhat restricted due to lack of water solubility. However, as Sahoo et al. 
developed the conjugated ZnPP, PEG-ZnPP, ZnPP achieved water solubility by micelle 
formation [52]. The PEG-part contributes to forming an aqueous layer on the 
compounds, so that the pegylated ZnPPs are safe from early blood clearance and PEG-
ZnPP achieves increased circulation time, as this compound behaves like 
macromolecules [84]. The benefits of pegylation include not only the water solubility, but 
also similar anticancer effects to ZnPP, and the character of macromolecule due to its 
molecular weight of about 68,000; this character contributes to the EPR effect. Several 
experimental studies have demonstrated that PEG-ZnPP could be considered as a 
promising anticancer agent due to its potential effects against various tumors [52, 72, 
85]. To our knowledge, so far there was no study investigating a potential efficacy of 
PEG-ZnPP on glioma cells, F98 and C6 in vitro and in vivo.  
 
6.1. Inhibition of Rat Glioma Cell Proliferation by PEG-ZnPP 
 
6.1.1. Effect of PEG-ZnPP via Apoptosis 
In this present study, we investigated if PEG-ZnPP inhibits proliferation of rat glioma 
cells.  Several studies proved the anticancer efficacy of PEG-ZnPP on tumor cells, 
including colon cancer and leukemic cells in vitro [72, 86]. Significant anti-proliferative 
activity of PEG-ZnPP in F98 glioma cell lines was found on day 6 in the present study. 
In order to explain the inhibition of proliferation, further in vitro studies, such as 
assessment of cell cycle and apoptosis, may be needed.   
Buttke and Sandstrom [87] reported that oxidative stress may be a potential mediator of 
apoptosis induction. The anti-inflammatory properties of HO-1 are due to its ability to 
degrade heme und generate bilirubin, free iron and carbon monoxide [16]. HO-1 plays a 
pivotal role for modulating inflammation by producing bilirubin, which protect cells from 
apoptosis. Bilirubin is one of the most abundant endogenous antioxidants in mammalian 
tissues and accounts for most of the antioxidant activity in human serum [40] and shows 
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scavenging activity against various oxidants including superoxide, peroxyradical, and 
peroxynitrite [40, 41]. 
 
Apoptosis, also referred to as programmed cell death, is a vital process which enables 
an organism to maintain homeostatic cell status by eliminating cells. This process also 
may occur as a defence mechanism for example, as immune reactions or when cells 
are damaged by toxic agents [88]. There are studies reporting the cytoprotective effect 
of HO-1 via anti-apoptotic effect in transplant injury during organ rejection, so that 
induction of HO-1 may protect cells from chronic inflammatory reactions [89, 90]. 
Increased expression of HO-1 is inevitable for long term survival after transplantation 
[90]. This suggests that the inhibition of HO activity makes tumor cells more susceptible 
to ROS [91, 92]. The cytotoxic effect of ZnPP and PEG-ZnPP due to specific inhibition 
of HO-1 can trigger the apoptotic pathway via caspase-3 cascade [72]. Tananka et al. 
reported enhanced caspase-3 activity in ZnPP treated hepatoma cells [53].  In addition, 
there are studies that NO, which is produced in excess during solid tumor growth, 
inhibits apoptosis via inhibition of the caspase protease cascade [93, 94]. Caspases 
appears as inactive procaspase that usually require dimerization and cleavage for 
further activation. Caspase-3 is known as an essential enzyme for apoptosis, which is 
activated by capase-8 in the extrinsic pathway or casepase-9 in the intrinsic pathway 
[95]. Extrinsic apoptosis is induced by extracellular ligands binding to death receptors 
and intrinsic apoptosis occurs due to factors released from the mitochondria, so that it is 
also known as mitochondrial apoptosis [95]. Via both pathways the caspase-3 can be 
activated and the apoptosis is triggered.   
HO-1 inhibition also causes enhanced transcription of p53 [96], which induces genes 
encoding the pro-apoptotic transcriptional target gene including, Bax, Puma, Noxa and 
Perp to activate the apoptotic pathway [97] . 
Tanaka et al. [53] used a siRNA to supress the expression of HO-1 incultured in a cell 
line of human colon adenocarcinoma, treating with ZnPP IX, in which antiapoptotic 
activity of HO-1 was confirmed.  
 
6.1.2. Effect of PEG-ZnPP on the Cell Cycle 
Additionally, assessment of the effect of PEG-ZnPP on the cell cycle phase can be 
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investigated. ZnPP can cause inhibition of hematopoesis in bone marrow, which may 
suggest that ZnPP could alter the cell cycle by inhibiting HO-1 [98].  HO-1 inhibition by 
administering ZnPP causes enhanced transcription of p53 [96], which plays a critical 
role in tumor supression. In various stress environments p53 protein, also referred to as 
cellular tumor antigen p53 and tumor suppressor p53, is responsible for regulating a set 
of its target genes and initiates stress responses including cell cycle arrest and 
apoptosis to execute tumor suppression [99, 100]. P53 induces the expression of p21, 
also known as cyclin-dependent kinase inhibitor 1 (CKI), which may cause apoptosis 
and cell cycle arrest by inhibiting cyclin/CdK complexes [101]. Active cyclin/CdK 
complexes inactivate members of the retinoblastoma protein (Rb) family by 
phosphylating it [102, 103]. Rbs are negative regulators of G1 and S-phase progression, 
which causes continuous cell cycle progression [102, 103]. CKIs can inhibit the activity 
of cyclin/CdK complexes so that the cell cycle progression can be negatively regulated 
[102, 103]. Yang et al. proved that the induction of p53 occurred depending on dose of 
ZnPP [96]. This may suggest that the p53 induction causes the arrest of G1 phase by 
inducing the expression of p21. Further experiments are required to determine the time 
course of the different processes occurring in our cells in response to PEG-ZnPP 
treatment, but we can speculate that PEG-ZnPP inhibits F98 and C6 glioma cell 
proliferation through the induction of cell cycle arrest, which could precede cell death 
processes. 
 
6.2. EPR Effect 
Pharmacokinetic study by Fang et al. [72] detected the increased amount of PEG-ZnPP 
biocompatible macromolecules in tumor tissue in a time-dependent manner. In addition, 
these macromolecules were decreased in systemic circulation gradually [72]. Increased 
size of molecule contributes to accumulation in tumor according to the EPR effect [68]. 
This tumor-specific accumulation of biocompatible macromolecules and lipids after 
systemic administration is due to its capacity to escape from renal clearance [68-71, 
104]. PEG-ZnPPs have a molecular size larger than 40,000, i.e., large enough to meet 
this criterion.  
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6.3. Antitumor Efficacy of PEG-ZnPP in vivo 
Based on the in vitro effect of PEG-ZnPP on proliferation and glioma cell death data, we 
investigated in vivo antitumor efficacy in rat glioma brainstem models. In contrast to our 
in vitro studies, no survival benefit of systemic therapy with PEG-ZnPP on rat glioma 
brainstem model was proven. To achieve an appropriate administering systemic dose of 
PEG-ZnPP, we have set up the initial dosage based on a previous study [72] and 
modified by equivalent surface area dosage conversion factors [79]. When it was given 
systemically, the adverse effect and toxicity of PEG-ZnPP were minor as all rats 
tolerated even the higher dosage of PEG-ZnPP well (from PEG-ZnPP equivalent 5 mg 
of ZnPP/kg to PEG-ZnPP equivalent 7.5 mg of ZnPP/kg). Higher dosage of PEG-ZnPP 
can be administered more than 3 times a week to achieve its maximal therapeutic dose. 
We speculate that the administered dose was close to maximum, which it may have 
reached. However, it might not be a matter of dosage or concentration but this particle 
may have difficulties to be delivered directly to brain tumor cells.  
Two main factors for the failure of chemotherapy in treatment of CNS tumors include 
natural or acquired resistance to chemotherapy expressed by tumor cells, and restricted 
delivery due to the blood-brain barrier (BBB) [105]. As the efficacy of PEG-ZnPP was 
confirmed in the present study, we speculate that the reason for failure of the systemic 
therapy is the inability of the substance to sufficiently cross the BBB. The impact of the 
BBB on chemotherapy is still controversial. However, it has been regarded that BBB is 
the main factor in the impaired efficacy of chemotherapy. The efficacy of 
chemotherapeutics in the treatment of brain tumor is often hampered due to the BBB.  
 
 
6.3.1. Brain-Blood Barrier  
 
Various chemical signals including neurotransmitters and modulators, and electrical 
signals including synaptic potentials and action potentials, which are inevitable for cell-
to-cell communication, require their own microenvironment, which protects the brain 
from variations in the blood. The BBB is necessary to provide an optimal environment 
for brain function. The BBB is composed with endothelial cells (EC) that form the walls 
of the capillaries, and its basement membrane, which is adjoined by tight junction 
protein. The endothelial cells are the core anatomical unit of the BBB, which prevent the 
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uncontrolled transport of water-soluble molecules between blood circulation system and 
brain parenchyma [106]. Pericytes and astroglial foot processes of astrocytes surround 
the ECs. These ECs are connected via adherent junctions, tight junctions and gab 
junctions. Tight junctions and adherent junctions underlie the physical barrier that 
impedes paracellular diffusion of ions, macromolecules and other polar solutes [107].  
Potential routes across the BBB for drugs and other solutes include passive diffusion, 
which is driven by concentration gradient, mainly for small hydrophobic 
therapeutics[108]. Most drugs which can cross the BBB, diffuse through membranes 
[109]. Other routes include carrier mediated efflux for glucose, amino acids and 
nucleosides [108], and tight junction modulation [110]. Non-polar solutes and lipid 
solubles may cross the BBB by passive diffusion and small peptides can transport the 
BBB via carrier mediate influx [110]. Polar solutes can cross via tight junction 
modulation relaxing the junctions [110].  
The normal BBB limits the permeation of ionized water-soluble compounds with a 
molecular weight > 180 daltons (D) [111]. Kroll et al. reported that most currently 
available effective chemotherapeutic agents have a molecular weight of 200-1200 D 
[112].  Pardridge reported [113] that almost all small drugs which are permeable to BBB 
are lipid soluble molecules with a weight less than 400 D [113]. A pharmacokinetic 
study confirmed that elution time of PEG-ZnPP was comparable to that of bovine serum 
albumin (67 kDa), which suggests that PEG- ZnPP behaves as large as BSA in an 
aqueous system [52].   
 
Drugs which can cross the BBB via diffusion show the following characters: a low 
molecular weight and lipophilicity. However, drugs taken up into membranes must have 
the capability to reach to the target after crossing the BBB to exert a therapeutic effect 
of anticancer. The character of lipid solubility may contribute to success in crossing the 
BBB, however, it can be easily sequestered by the capillary bed and not reach the 
target [114]. Therefore, the drugs should meet at least two criteria: they should have 
characters which can cross the BBB and reach the tumor after crossing the BBB. These 
are the prerequisites for the success of systemic chemotherapy for CNS malignancy. 
The hydrophilic property of  PEG-ZnPP, which is gained due to conjugation with the 
PEG-chain [52] can be regarded as another additional limitation to crossing the BBB. 
However, the lipophilicity of substance as a benefit for crossing the BBB applies to 
small drugs, which can cross the BBB via diffusion.  
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6.3.1.1. Transport of Macromolecules 
 
Transport of macromolecules requires both specific and nonspecific interaction between 
macromolecules and receptors expressed on the luminal and the abluminal surfaces of 
the brain capillary endothelial cells [115]. Endocytosis and transcytosis play an 
important role for macromolecues [115]. Endocytosis is a type of active transport on 
which a cell transports different compounds into itself by forming vesicles. When 
compounds and macromolecules are expelled into the other side, it is termed as 
transcytosis [115]. Adsorptive-mediated transcytosis (AMT) and receptor-mediated 
transcytosis (RMT) are the main vesicular mechanism for large molecules to cross the 
brain endothelium [116]. In the AMT pathway, positively charged peptides interact with 
the negatively charged membrane surface, so that membranes can be invaginated via 
forming vesicles [117]. RMT systems are selective pathways to cross the BBB through 
the initial binding of a ligand to receptor-mediated RMT receptors. The RMT pathway is 
known as a favourable delivery pathway for toxic agents. Generally, transporting 
macromolecules via tight junction is not possible [115]. 
 
Even though the BBB is often regarded as a main factor of failure of chemotherapy in 
CNS, we must acknowledge that there is objection to the fact that the integrity of the 
BBB in the center of malignant brain tumors is disturbed [105]. This leaky BBB is 
heterogeneous [105], variable and dependent on the tumor type and size [112]. Even 
though the BBB of malignant glioma is interrupted and fenestrated for unimpeded 
passage of low molecular weight particles [118], such endothelial disruption due to 
discontinuities of endothelial cells of tumor microvessels may not be wide enough for 
the effective passage of PEG-ZnPP particles and to achieve therapeutic efficacy.  
Another explanation, which may limit the systemic chemotherapeutic efficacy, is the 
“sink effect” [119] . The hydrostatically driven flow of CSF, which begins from ventricles 
via subarachnoid space to venous blood, contributes to a strong diffusion gradient to 
lower ECF metabolites and catabolites being produced by parenchymal cells in brain 
[120]. This capacity to lower the “steady state” of drugs [119] delivered to the CNS, may 
also contribute to a diminished chemotherapeutic concentration and lead to therapy 




6.4. Alternative Approach 
 
So far, we have to admit that as long as solutions to the BBB problem are not found, 
there are only few effective treatments for CNS malignancies including brainstem 
tumors. PEG-ZnPP may have a limited penetrance to the BBB, however, it could still 
represent a potential agent against brainstem tumor, if the compound could be locally 
delivered to its targeted localization. Currently a lot of research is on-going in the field of 
nanoparticles to overcome this obstacle by enhancing PEG-ZnPP bioavailability. Local 
delivery of antitumor therapeutic agents into the brain allows compounds to bypass the 
BBB. The bulk-flow properties of convection enhanced delivery (CED) contributes to a 
relatively homogeneous concentration of large molecules [121, 122]. The compounds, 
which do not readily penetrate the BBB from the systemic circulation when they are 
delivered by convection enhanced delivery, remain sequestered on the abluminal side 
of the BBB within the perfused parenchyma for prolonged periods, until they are 
metabolized and cleared from the interstitial spaces [123-126]. These compounds do 
not readily leak through the CNS blood vasculature in CNS and into the systemic 
circulation. There are studies which demonstrated the possible use of CED in a rat brain 
stem model [127, 128]. Further investigations are clearly required to clarify that local 
delivery of PEG-ZnPP is technically possible, and the toxicity effect of PEG-ZnPP on 
normal brain and tumor in vivo studies. 
 
7. Conclusion 
The present in vitro study proved that PEG-ZnPP, a specific inhibitor of HO-1, has a 
potential antitumor effect against glioma cell lines including C6 and F98. However, 
despite its anti-proliferative efficacy via enhanced activity of apoptosis on glioma cells, 
no survival benefit in the rat brainstem glioma model was observed in the in-vivo 
experiments. We speculate that it is mainly due to limited permeability of PEG-ZnPP 
through the BBB into the tumor. For the clinical application of PEG-ZnPP, further 
investigation should be guaranteed to find better approaches to deliver the PEG-ZnPP 
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